Bone substitution in revision hip replacement.
The aim of this retrospective study was to report the preliminary results of femoral peri-prosthetic bone defect reconstruction with a synthetic bone substitute. Twenty-one revisions of the femoral component in 20 patients were evaluated. The mean age at operation was 65.7 years (range, 30 to 79 years). Preoperative femoral deficiencies were rated grade II in 7 cases and grade III in 14 cases according to the SOFCOT classification. None was rated grade IV. Femoral revision was indicated for loosening in 18 hips (including 8 septic cases), femoral osteolysis (1 hip), persistent pain (1 hip) and recurrent dislocation (1 hip). Once the loose prosthesis had been removed, calcium phosphate ceramic (CPC) granules (14 cases) or ceramic granules + cancellous allograft (5 cases) or autograft (2) were firmly impacted in the femoral canal. The stem was standard and always cemented using modern cementing technique. At a mean follow-up of 36 months (range, 14 to 76 months), 90% of the hips were rated good or very good according to the Merle d'Aubigné score. Two diaphyseal femoral fractures occurred and later united. Two hips required re-revision (aseptic loosening; septic recurrence). The absence of radiological osteolysis in 17 cases suggested direct bonding between ceramic granules and bone. Stem subsidence occurred in two cases and was limited (5 and 8 mm). Femoral bone reconstruction using impacted CPC or CPC in conjunction with bone graft in revision hip replacement commonly provided restoration of the bone stock in the short to mid-term. Further long-term studies will be necessary to support this conclusion.
Nich
C
C
Department of Orthopaedic Surgery, Lariboisiere Hospital, University of Paris VII, Paris, France. chrnich@gmail.com
Sedel
L
L
D000328:Adult; D000368:Aged; D019644:Arthroplasty, Replacement, Hip / Q000379:methods*; D001672:Biocompatible Materials / Q000627:therapeutic use*; D002130:Calcium Phosphates / Q000627:therapeutic use*; D002516:Ceramics / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006882:Hydroxyapatites / Q000737:chemistry / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D020127:Recovery of Function; D012086:Reoperation / Q000009:adverse effects / Q000379:methods; D012189:Retrospective Studies; D016896:Treatment Outcome
D001672:Biocompatible Materials; D002130:Calcium Phosphates; D006882:Hydroxyapatites; C475044:hydroxyapatite cement; C020243:calcium phosphate